Prurigo as the early sign of HIV infection: a review
DOI:
https://doi.org/10.18203/2349-3933.ijam20251085Keywords:
Antiretroviral therapy, Cytokines, HIV, Inflammation and pruritus, Prurigo nodularisAbstract
Prurigo is a common dermatological condition in HIV-infected individuals, particularly those with low CD4 counts. This condition can be the first manifestation and as the early sign of HIV-infected individuals. One form of prurigo in HIV-positive patients is prurigo nodularis. It presents with intensely pruritic, hyperkeratotic papules or nodules lesions, significantly impairing quality of life. The pathogenesis of PN involves complex immune dysregulation, including Th2-mediated inflammation and the release of cytokines like IL-31, which contribute to inflammation and pruritus. HIV infection exacerbates these processes, making PN more prevalent and severe in immunocompromised individuals. Early detection of prurigo and appropriate treatment, including rapid antiretroviral therapy, can help reduce the frequency and severity of prurigo in HIV-positive patients. Current treatments include topical steroids, UV therapy and systemic medications, with novel therapies targeting specific cytokines under investigation. Dermatologists are also encouraged to screen for psychiatric comorbidities due to the profound psychosocial impact of PN. This review aims especially for health workers to remind the importance of early detection of dermatological signs of prurigo in patients at risk of HIV, as an important step in improving clinical outcomes and patient quality of life.
Metrics
References
Criado PR, Ianhez M, Criado RF, Nakano J, Lorenzini D, Miot HA. Prurigo: review of its pathogenesis, diagnosis, and treatment. Anais Brasileiros De Dermatologia. 2024;99(5):706-20. DOI: https://doi.org/10.1016/j.abd.2023.11.003
Akar HH, Tahan F, Balkanli S. Prurigo simplex subacuta or prurigo simplex acuta. European Ann Allergy Clin Immunol. 2014;46(4):152-3.
Pereira MP, Ständer S. How to define chronic prurigo? Experimental Dermatol. 2019;28(12):1455–60. DOI: https://doi.org/10.1111/exd.13972
Karabinta Y, Konaté I, Dicko A, Cisse L, Samaké M, Touré A, Traoré B, Fofana Y, Touré S, Faye O, Dao S. Epidemiological and clinical aspects of prurigo in HIV infected patients in Fousseyni N'Daou hospital of Kayes, Mali. Le Mali Medical. 2018;33(2):13-6.
Matthews SN, Cockerell CJ. Prurigo nodularis in HIV-infected individuals. International J of Dermatol. 1998;37(6):382. DOI: https://doi.org/10.1046/j.1365-4362.1998.00507.x
Motegi SI, Kato M, Uchiyama A, Yamada K, Shimizu A, Amano H, Ishikawa O. Persistent prurigo nodularis in HIV-infected patient responsive to antiretroviral therapy with raltegravir. The J of Dermatol. 2014;41(3):272-3. DOI: https://doi.org/10.1111/1346-8138.12408
Tolomeo M, Cascio A. The complex dysregulations of CD4 T cell subtypes in HIV infection. International J of Molecular Sciences. 2024;25(14):7512. DOI: https://doi.org/10.3390/ijms25147512
Rook AH, Rook KA, Lewis DJ. Interleukin-31, a potent pruritus-inducing cytokine and its role in inflammatory disease and in the tumor microenvironment. Tumor Microenvironment: The Role of Interleukins–Part B. 2021: 111-27. DOI: https://doi.org/10.1007/978-3-030-55617-4_8
Garcovich S, Maurelli M, Gisondi P, Peris K, Yosipovitch G, Girolomoni G. Pruritus as a distinctive feature of type 2 inflammation. Vaccines. 2021;9(3):303. DOI: https://doi.org/10.3390/vaccines9030303
Girolomoni G, Maurelli M, Gisondi P. The emerging role of the neuroimmune cytokine interleukin-31 in chronic inflammatory skin diseases. Italian J Dermatol and Venereol. 2022;157(4):306-12. DOI: https://doi.org/10.23736/S2784-8671.22.07265-6
Furue M, Furue M. Interleukin-31 and pruritic skin. J Clin Med. 2021;10(9):1906. DOI: https://doi.org/10.3390/jcm10091906
Stucky CL, Mikesell AR. Cutaneous pain in disorders affecting peripheral nerves. Neuroscience letters. 2021;765:136233. DOI: https://doi.org/10.1016/j.neulet.2021.136233
Fujii M. Current understanding of pathophysiological mechanisms of atopic dermatitis: interactions among skin barrier dysfunction, immune abnormalities and pruritus. Biological and Pharmaceutical Bulletin. 2020;43(1):12-9. DOI: https://doi.org/10.1248/bpb.b19-00088
Hatano Y, Elias PM. “Outside-to-inside,”“inside-to-outside,” and “intrinsic” endogenous pathogenic mechanisms in atopic dermatitis: keratinocytes as the key functional cells involved in both permeability barrier dysfunction and immunological alterations. Fron Immunol. 2023;14:1239251. DOI: https://doi.org/10.3389/fimmu.2023.1239251
Yang G, Seok JK, Kang HC, Cho YY, Lee HS, Lee JY. Skin barrier abnormalities and immune dysfunction in atopic dermatitis. International J Molecular Sciences. 2020;21(8):2867. DOI: https://doi.org/10.3390/ijms21082867
Cornman HL, Whang KA, Ma E, Aggarwal P, Kambala A, Reddy SV, et al. Severity, impact on quality of life and mental health burden of pruritus in prurigo nodularis: a cross-sectional study of a diverse patient cohort. British J Dermatol. 2024;190(4):571-2. DOI: https://doi.org/10.1093/bjd/ljad500
Huang TL, Li CF, Huang HY, Fang FM. Correlations between expression of epidermal growth factor receptor (EGFR), phosphorylated EGFR, cyclooxygenase-2 and clinicopathological variables and treatment outcomes in nasopharyngeal carcinomas. Chang Gung Med J. 2010;33(6):619-27.
Kwon CD, Khanna R, Williams KA, Kwatra MM, Kwatra SG. Diagnostic workup and evaluation of patients with prurigo nodularis. Medicines. 2019;6(4):97. DOI: https://doi.org/10.3390/medicines6040097
Elmariah S, Kim B, Berger T, Chisolm S, Kwatra SG, Mollanazar N, Yosipovitch G. Practical approaches for diagnosis and management of prurigo nodularis: United States expert panel consensus. J American Acad of Dermatol. 2021;84(3):747-60. DOI: https://doi.org/10.1016/j.jaad.2020.07.025
Chatterjee R, Samajdar SS, Mukherjee S. Dermatological manifestations of HIV: Implications for esthetic and clinical management. Aesthetics International. 2024;2(1):9-18. DOI: https://doi.org/10.4103/ASIL.ASIL_10_24
Kabashima K, Irie H. Interleukin-31 as a clinical target for pruritus treatment. Frontiers in medicine. 2021;8:638325. DOI: https://doi.org/10.3389/fmed.2021.638325
Downloads
Published
How to Cite
Issue
Section
